A number of clinical trials have confirmed the effectiveness of anti-HER2 therapy, such as the HERA, NCCTG N9831, NSABP B-31, BCIRG 006, and TC4H trials.[18] The Neo Sphere trial demonstrated that anti-HER2 therapy should be administered in conjunction with chemotherapy for the best treatment effect.[19] Thus, for HER2-positive breast cancer, chemotherapy is as indispensable as anti-HER2 therapy. Here, ERAL1 is linked to breast cancer.